A one-dimensional drug delivery system (1D DDS) is highly attractive since it has distinct advantages such as enhanced drug efficiency and better pharmacokinetics. However, drugs in 1D DDSs are all encapsulated in inert carriers, and problems such as low drug loading content and possible undesirable side effects caused by the carriers remain a serious challenge. In this paper, a novel, carrier-free, pure drug nanorod-based, tumor-targeted 1D DDS has been developed. Drugs are first prepared as nanorods and then surface functionalized to achieve excellent water dispersity and stability. The resulting drug nanorods show enhanced internalization rates mainly through energy-dependent endocytosis, with the shape-mediated nanorod (NR) diffusion process as a secondary pathway. The multiple endocytotic mechanisms lead to significantly improved drug efficiency of functionalized NRs with nearly ten times higher cytotoxicity than those of free molecules and unfunctionalized NRs. A targeted drug delivery system can be readily achieved through surface functionalization with targeting group linked amphipathic surfactant, which exhibits significantly enhanced drug efficacy and discriminates between cell lines with high selectivity. These results clearly show that this tumor-targeting DDS demonstrates high potential toward specific cancer cell lines.
Introduction
During the past few decades, interest in the design of nanotechnology-based drug delivery systems (nanoDDSs) has been increasing because of the favorable physical, chemical, and biological properties of biomolecules of that size [1] [2] [3] [4] [5] [6] . Among the various nanoDDSs, one-dimensional (1D) nanocarriers have received steadily growing interest [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] because of their unusual and fascinating geometric features, which are superior to their zero-dimensional nanoparticle (NP)-based counterparts. Cylindrical nanovehicles exhibit better pharmacokinetics and efficiency in drug delivery than spherical ones because of their enhanced internalization rates, multiple endocytotic mechanisms, and more effective adhesion to the target cell surface [19] [20] [21] [22] [23] . Moreover, cylindrical DDSs can simultaneously bind different functional modules in a spatially defined manner [24] .
Despite the numerous developments and distinct advantages of 1D nanoDDSs, drugs remain encapsulated in inert carriers, which may bring some serious problems. One problem is the low drug loading capacity, because the carriers are usually the major component of the system and are far heavier than the drugs themselves (which generally comprise less than 10% of the weight) [25, 26] . Another problem is the inherent systemic toxicity and undesirable side effects typically associated with the carriers [27] . Drug carriers are typically inert and act only as vehicles; however, their presence could increase the systemic toxicity of the drug formulation, and their subsequent degradation could pose a potential problem which would impose an extra burden on patients. Finally, the synthesis of most carriers is usually difficult and time consuming [28] [29] [30] . Other challenges that need to be addressed include the effective loading of the drugs into the carriers and the homogeneous dispersion of DDSs in the presence of proteins normally present in physiological fluids. Therefore, the development of alternative delivery strategies with minimum use of inert materials and maximum therapeutic efficacy is highly desirable.
In this paper, a novel, carrier-free, pure drug nanorod (NR)-based delivery system consisting of anticancer drug NRs as the core and tumor-targeting modules on the NR surfaces as the shell was devised for the first time. The efficiency and selectivity of this system in delivering anticancer drugs to the tumor cells were then determined. Paclitaxel (PTX), a well-known broad spectrum antitumor drug against various cancers [31] [32] [33] [34] [35] , was used as the model hydrophobic anticancer drug to verify the feasibility of the proposed strategy. PTX was first prepared into NRs and then surface functionalized with targeting group linked amphipathic surfactant to achieve a targeted drug delivery system that exhibits significantly enhanced drug efficacy and discriminates between cell lines with high selectivity. Pure drug NRs, with no added inert external agent, were used as the carriers in this approach, resulting in substantially increased drug loading content and reduced risk to patients. More importantly, a more effective internalization process and significantly improved drug efficiency that is nearly 10 times higher than that of free PTX molecules and unfunctionalized NRs was observed for the functionalized drug NRs. These results clearly illustrate the advantages of the nanoDDS developed using this strategy. The strategy described here can be useful in the design and fabrication of novel drug formulations, as well as in the determination of potential applications in advanced therapeutic and diagnostic oncology.
Experimental methods

Materials and measurements
Paclitaxel (purity > 99%) was purchased from Knowshine (Shanghai, China). Poly(maleicanhydride-alt-1-octadecene) (PMHC18), mPEG-NH 2 (5K), NH 2 -mPEG (5K)-tertbutoxycarbonyl (BOC) (PEG, polyethylene glycol; BOC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St Louis, MO, USA) and used after drying in a vacuum for 24 h. 4-(dicyanomethylene)-2-tert-butyl-6-(1,1,7,7-tetramethyljulolidin-4-yl-vinyl)-4H-pyran (DCJTB) was purchased from J&K Scientific Ltd. Folic acid (FA), N-hydroxy succinimide (NHS), dimethyl sulfoxide (DMSO), absolute ethanol, dichloromethane (DCM) and triethylamine (TEA) were purchased from Sinopharm Chemical Reagent Co., Ltd. Roswell Park Memorial Institute-1640 (RPMI-1640) medium, FA-free RPMI-1640, fetal bovine serum (FBS), Dulbecco's phosphate buffered saline (PBS), trypsin-EDTA (0.5% trypsin, 5.3 mM EDTA tetra-sodium), and penicillin-streptomycin solution were purchased from Invitrogen (San Diego, CA, USA). High-purity water with a resistivity greater than 18.2 M cm was obtained from a Milli-Q Biocel water purification system (Millipore Corporation, Bedford, MA, USA). Unless otherwise noted, all the chemicals were obtained from commercial suppliers and used without further purification.
UV-vis absorption spectra were measured by a PerkinElmer Lambda 750 UV/vis/NIR absorbance spectroscope. Scanning electron microscopic (SEM) images were obtained on a FEI Quanta 200 FEG field emission scanning electron microscope operated at an accelerating voltage of 10 kV. Transmission electron microscopy (TEM) images were taken from FEI Tecnai G2 F20 S-TWIN operated at an accelerating voltage of 200 kV.
Preparation and functionalization of PTX NRs
PTX NRs were prepared by an anti-solvent precipitation method [36, 37] . In brief, 200 µl of 3 mg ml −1 PTX/ethanol solution was poured into 5 ml of deionized water at room temperature under vigorous stirring and the NRs were obtained by moderate sonication. PMHC18-PEG and FA-PEG-PMHC18 were synthesized following a literature procedure [38] . For functionalization of PTX NRs, 100 µl of PMHC18-PEG/H 2 O or FA-PEG-PMHC18/H 2 O (1 mg ml −1 ) was added into 1 ml of PTX NR suspension. The mixture was then stirred for 0.5 h. Afterwards, amphipathic polymers would be readily anchored to the surface of PTX NRs by noncovalent hydrophobic interaction.
Storage stability study
The suspensions of functionalized and unfunctionalized PTX NRs were stored at room temperature. Digital photographs of the samples were measured at 0-3 and 6 months. The PTX content was also monitored by UV-vis.
In vitro drug-release assay
To measure releasing behavior, PMHC18-PEG and FA-PEG-PMHC18 functionalized PTX NRs were diluted by PBS, pH 7.4, to 60 µM liter −1 . Eight milliliters of the suspension was added into a dialysis bag (3500 molecular weight cut-off, Fisherbrand R , Pittsburgh, PA, USA) that was then immersed in 200 ml of PBS at 37 • C under constant shaking. Aliquots of 3 ml were withdrawn at a predetermined time from the solution to containers. The solution volume was kept constant by adding 3 ml of fresh PBS after each sampling. The amount of PTX released was determined by UV-vis absorbance spectroscopy. For comparison, PTX bulk powder and unfunctionalized NRs diluted in PBS were also tested by the same procedure. The drug-release assays were carried out three times and the average value of the three measurements was taken.
Cell culture
A human nasopharyngeal epidermal carcinoma cell line (KB cells) was provided by the American type culture collection (ATCC). It was cultured in both normal and FA-free RPMI-1640 culture medium with 10% FBS and 1% penicillin-streptomycin solution at 37 • C in a humidified atmosphere containing 5% CO 2 . The concentration of FA in serum-containing FA-free medium is only 3 nM, as opposed to 2.26 µM under normal culture conditions. Cells were routinely passed by treatment with trypsin (0.05%)/EDTA. Cells for toxicity testing were used in the exponential growth phase.
Confocal laser scanning microscopy
Confocal imaging of cells was performed using a Leica laser scanning confocal microscope. KB cells were seeded in a 24-well cell-culture plate for 24 h (37 • C, 5% CO 2 ), the DCJTB-doped PTX NRs (PTX = 6 µM l −1 ) were added to the wells. Cells were then incubated for 15 min, 30 min, 1, 2, and 4 h (37 • C, 5% CO 2 ). After being washed three times with PBS, the cells were then fixed with 4% paraformaldehyde. Imaging of NRs was carried out under 514 nm laser excitation and the emission was collected in the range of 550-650 nm. Cells incubated in the absence of the NRs were used as the control.
Cytotoxicity assays
The in vitro cytotoxicity was measured using a standard MTT assay. KB cells were seeded into 96-well cell-culture plate at 100 µl/well and then incubated for 24 h at 37 • C under 5% CO 2 . After incubating with various concentrations of free PTX, unfunctionalized PTX NRs, and functionalized PTX NRs for 24, 48, and 72 h, respectively, the standard MTT assay was carried out to determine the cell viabilities relative to the control untreated cells.
For the FA targeted PTX delivery experiment, KB cells cultured in FA-free RPMI-1640 medium with high folate receptor (FR) expression were used as positive cells, while KB cells cultured in normal RPMI-1640 medium with low FR expression were used as the negative control. Both cells were incubated with series concentrations of PTX solution, unfunctionalized NRs, PMHC18-PEG-functionalized NRs and FA-PEG-PMHC18 functionalized NRs for 6 h first and then changed to fresh medium after washing. After another 24 h incubation, the cell viability was measured by MTT assay.
Results and discussion
3.1. Assembly of the engineered nanorod drug formulation and receptor-mediated internalization Scheme 1 shows the four key steps involved in the assembly of surface-functionalized drug NRs and their targeted endocytosis. In the first step, the drugs are prepared into pure drug NRs without the addition of any inert materials; this approach is different from that for conventional carrier-based DDSs. Trace/small amounts of the surfactant are added in the second step for the surface functionalization of the NRs to achieve biocompatibility and stability. The specific targeting ligand is introduced to the NR surface for selective drug accumulation. In the third step, the functionalized NRs are internalized into the tumor cells through receptor-mediated endocytosis. The FA moieties covalently attached to the PMHC18-PEG methyl ethers efficiently recognize the FRs that are overexpressed on the tumor cell surfaces. The presence of multiple folate moieties enhances the internalization of the NRs via increased opportunities for receptor binding. In the last step, the active drug molecules are released from the NRs and then bind to tubulins/microtubules, resulting in the inhibition of cell mitosis at the G2/M stage through the stabilization of the microtubules, which triggers apoptosis [39, 40] .
In this process, the drug loading content is substantially increased compared with that in the carrier-based DDSs, and the additional carrier toxicity and metabolism burden are significantly reduced. As a result, the efficiency of the cancer treatment is remarkably improved.
Preparation and characterization
PTX NRs were prepared using the solvent exchange method [36, 37] . Two amphiphilic stabilizers, namely PMHC18-PEG and FA-PEG-PMHC18, were designed and synthesized according to the previous reports [38] . The morphology and structure of the NRs were investigated via SEM and TEM. The SEM micrograph ( figure 1(a) ) shows the rodlike morphology of the samples. The NRs can be obtained in large scale, with a uniform length of less than 500 nm and a diameter of 40 nm. In addition, the TEM result is consistent with that deduced from the SEM image ( figure 1(b) ).
A high drug loading capacity is essential for nanomedicines in parenteral applications and can reduce the carrier dosage, thereby minimizing the possible side effects. Drug loading efficiency was defined as the ratio of the weight of PTX to that of the entire NR. In this system, the loading degree of PTX is estimated at 93 wt%. Such a high drug loading content is beneficial for the carrier-free strategy and can resolve the inherent problem of low drug loading capacity for nanomedicines with carriers.
Water-dispersibility, stability, and drug-release profiles
The functionalized NR suspension had a homogeneous milky white color and exhibited excellent dispersal in PBS even after 6 months. On the other hand, the unfunctionalized NRs formed large agglomerations and precipitated at the bottom, leaving behind a rather clear supernatant ( figure 1(c) ) due to the elimination of the surface charge of NRs by zwitterions in PBS. The UV-vis absorptions of the supernatant of the resulting unfunctionalized and functionalized NR PBS suspensions were also measured. Figure 1(d) shows the strong absorptions exhibited by the functionalized NR PBS suspensions, whereas almost no signal can be detected in the spectra of the unfunctionalized NR PBS suspensions because of the precipitation of most of the PTX molecules. These results show that surface functionalizations endow the PTX NRs with excellent dispersal in water and outstanding stability in physiological environments, thereby making in vitro drug delivery possible.
The cumulative drug-release profiles of the PTX powder and the unfunctionalized and functionalized NRs as a function of the release time were further examined in a simulated body fluid (PBS) (figure 2). The released PTX concentrations were determined via UV-vis measurement of the supernatants from the PTX samples after centrifugation for different times. The drug powder exhibits approximately 18 wt% drug-pronounced initial burst release within 1 h and reaches about 22 wt% of sustained release within 200 h, whereas that of functionalized (unfunctionalized) NRs is enhanced by 10% (20%) and 40% (60%), respectively. The remarkable increase in the release rate of the nanodrugs is attributed to the increased surface area and dissolution velocity, which results from the reduction in size.
Cellular internalization of PTX NRs
The cellular uptake of PTX NRs was examined using the KB cell line and investigated via confocal laser scanning fluorescent microscopy (CLSM) by monitoring the red fluorescence of DCJTB, a red fluorescent dye with high quantum yield, which was doped into the PTX NRs for labeling. The results show that the internalization of PTX NRs is prompt and reaches a plateau after incubation for 2 h (figure 3). In the initial stage, almost no signal was observed in the cells, and the fluorescence gradually appeared as the incubation time was prolonged. After incubation for 2 h ( figure 3(c) ), a strong fluorescence with high signal-to-background ratio was observed; this signal was kept almost constant afterwards.
The mechanism for the internalization of NRs into the cells has not been fully understood. However, NRs may be internalized into cells through endocytosis and shape-induced penetration, similar to the internalization process of carbon nanotubes [41, 42] . PTX NRs are assumed to act as nanoneedles that pierce through cell membranes, thereby allowing their diffusion into the cells.
Endocytosis is known to be energy dependent and can be inhibited by low temperatures. KB cells were incubated with the NRs at 4 and 37 • C to identify the mechanism of the cellular uptake of the NRs. Strong red fluorescence signals were detected from cells incubated at 37 • C (figures 4(c), (d)), whereas the signal at 4 • C was relatively weak but was still observable after 2 h of incubation (figures 4(a) and (b)). This phenomenon indicates that energy-dependent • C for 30 min, (b) 4
• C for 2 h, (c) 37
• C for 30 min, (d) 37
• C for 2 h. After NR incubation, the cells were washed and transferred into a fresh cell medium for further incubation for 6 h. Time-dependent confocal images of KB cells incubated with DCJTB-doped NRs at 37
• C after post-incubation for (e)-(g) 10 min, (h) 30 min, (i) 2 h, and (j) 4 h. All images were taken under identical instrumental conditions and are presented at the same intensity scale. Arrows point to the NRs that are ready to enter the cells. endocytosis is dominant in the internalization process. However, the shape-induced penetration also makes a contribution based on the detected fluorescence signals at 4 • C. A time-dependent CLSM image was monitored (figures 4(e)-(j)) to understand the internalization process better. During the early incubation stage, NRs adhered to the cell membrane in all directions (marked in figures 4(e)-(g)), then quickly moved perpendicular to the cell membrane. Such a pathway dominated the endocytosis process (figures 4(h)-(j)). Some bundle-like architectures were occasionally observed, possibly resulting from the aggregation of PTX NRs in a physiological environment ( figure 4(j) ). These results clearly show that the PTX NRs can be effectively absorbed by the KB cells mainly through energy-dependent endocytosis, with the shape-mediated NR diffusion process as a secondary pathway.
In vitro cytotoxic activity
After confirming the stability and internalization of the functionalized PTX NRs, the cytotoxicity of NRs against the KB cells was determined via the MTT assay to investigate their potential as versatile vehicles for tumor-targeted drug delivery. This method is based on the formation of dark red formazan by the metabolically active cells after their exposure to MTT. Cell viability is directly proportional to the amount of formazan produced, which is monitored through the absorbance at 570 nm. KB cells were incubated with free PTX, unfunctionalized, and functionalized PTX NRs at exposure times of 24, 48, and 72 h prior to the MTT assay. The results show that the cytotoxicity of PMHC18-NRs was 10 times higher than that of the free PTX and unfunctionalized NRs in terms of the half-maximal inhibitory concentration (IC50; figures 5(a)-(c) ), implying that the apparent cytotoxicity per PTX is substantially increased with the use of NR-based DDSs. The improved drug efficiency may be due to the more effective internalization of functionalized NRs compared with that of unfunctionalized NRs and molecules. When unprotected drug molecules are exposed to the cells, only the concentration-dependent penetration force drives the PTX into the cancer cells, resulting in the internalization of only a very small part of the extracellular PTX. On the other hand, PTX delivered into the cancer cells through the DDS can be quickly released and tightly binds to the target protein (tubulins/microtubules), resulting in significantly higher effective intracellular drug concentration compared with that achieved via extracellular exposure of the drug. The time-dependent cytotoxicities of free PTX, unfunctionalized, and functionalized PTX NRs were also assessed ( figures 5(d)-(f) ). The cytotoxicities were all gradually enhanced within a 72 h time frame.
The KB cells were also treated with PMHC18-PEG and FA-PEG-PMHC18 over a range of dosages (0.0-200 µg ml −1 ) to serve as the control experiments. The results show more than 95% cell viability for all concentration ranges (figure 6), suggesting that the observed cytotoxicity is attributed to the PTX molecules released from internalized NRs. Moreover, the two surfactant materials are nontoxic and show promise in biomedical applications.
Tumor-targeting specificity through receptor-mediated endocytosis
The targeted delivery of a drug to specific organs or cells can potentially maximize its therapeutic efficacy while minimizing the side effects [43, 44] . The FR is a versatile cancer cell probe that is overexpressed in many types of cancer cells. Numerous reports have confirmed the targeting effect of FA in killing tumor cells [5, 38, [45] [46] [47] . Therefore, FA was introduced to the PEG terminals of the PMHC18-PEG polymer, and the product, FA-PEG-PMHC18, was then used to functionalize the PTX NRs. shows that the FA-NRs exhibited distinctly improved toxicity against the FR(+) KB cells, which is attributed to the accelerated intracellular PTX delivery due to the folate conjugated on their surfaces. On the other hand, no obvious change in cytotoxicity was observed for the PMHC18-PEG and FA-PEG-PMHC18 functionalized NRs in the control experiment for the FR(−) KB cells ( figure 7(f) ). To verify further the specificity of FR-mediated targeting, the folate receptors on the surfaces of the KB cells were blocked by adding excess free FA before incubation of the cells with FA-NRs. Considerably weaker cell toxicity was observed in the blocked cells ( figure 8) . The results clearly demonstrate the highly specific FR targeting of the FA-conjugated NR system and confirm the potential application of FA-NR-based DDSs for active ligand-specific cancer therapy.
Conclusions
In summary, a novel, carrier-free, pure drug NR-based DDS with high drug loading content and desirable stability has been developed for targeted drug delivery and cancer treatment. PTX was used as the model drug to verify the efficiency of this DDS. The experimental results show that PMHC18-PEGfunctionalized PTX NRs entered the cells mainly through energy-dependent endocytosis, with the shape-mediated NR diffusion process as a secondary contributing pathway. Drug efficiency was obviously improved, with the cytotoxicity of the functionalized PTX NRs exhibiting 10 times higher efficiency compared with that of the free PTX molecule and unfunctionalized NRs. A targeted DDS was also achieved through simply linked targeting groups on the surface of NRs; the FA-functionalized NRs demonstrated a remarkable cell-killing ability compared with the nontargeted ones. These results strongly suggest that the functionalized drug NR-based DDS can be a highly promising drug delivery platform that offers (1) a biomarker-targeted drug delivery, (2) possible delivery of greater therapeutic payloads, and (3) possible use of multiple complementary drugs for combination therapy. Future work will be devoted to the in vivo delivery of functionalized NRs for cancer therapy, as well as continued optimization of stimulus responsibility and the development of a multifunctional synergistic nanoplatform.
